ClinicalTrials.gg
RecruitingNCT06114667HiCOPDUpdated Jun 22, 2026

Nasal High Flow Versus Non-invasive Ventilation for Early Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Hypercapnic Acidosis

An interventional study of Ventilatory support via nasal high flow and Ventilatory support via NIV in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Hypercapnic Acidosis and Respiratory Failure With Hypercapnia, sponsored by University Hospital, Montpellier. Recruiting at 3 sites in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether nasal high flow is non inferior to non invasive ventilation (NIV) in the early treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and hypercapnic acidosis in the emergency department (ED). After obtaining informed consent, participants will be randomly assigned to receive either nasal high flow or non invasive ventilation (NIV, reference treatment) as respiratory support. Researchers will compare both respiratory support groups to see if their blood gas analysis and respiration return to normal ranges.

Read the detailed description

Prospective multicenter comparative therapeutic study, with a randomized controlled parallel and open design. Nasal high flow will be compared to NIV (reference treatment) for early treatment of AE-COPD associated with hypercapnic acidosis.

Adult patients admitted to the ED for AE-COPD with hypercapnic acidosis will be randomized to receive either nasal high flow or NIV as ventilatory support. Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment. Close monitoring of clinical and gas parameters will be conducted with repeat assessment and serial blood gas testing at 2h and after each 2h session of respiratory support in the ED (2h, 4h, 6h) and at 24h.

Standard oxygen therapy will be administered as required between ventilatory support sessions to maintain a target peripheral oxygen saturation (SpO2 : 88-92%).

Patient's dyspnea and comfort will be assessed before treatment and at 2h, and after each respiratory support session in the ED Patients will receive standard medical treatment for AE-COPD (bronchodilator, corticosteroids and antibiotics) according to current practice and 2023 global initiative guidelines for the management of COPD (GOLD).

Patients will be followed up at day 28 by means of medical records review and telephone interview

02

Conditions studied

  • Acute Exacerbation of Chronic Obstructive Pulmonary Disease
  • Hypercapnic Acidosis
  • Respiratory Failure With Hypercapnia

Keywords

  • respiratory insufficiency
  • Hypercapnic Acute Respiratory Failure
  • chronic obstructive pulmonary disease exacerbation
  • nasal high flow
  • non invasive ventilation
  • emergency department
  • critical are
03

In context

Acidosis, Respiratory

22 studies on the registry are indexed under Acidosis, Respiratory; 6 are open to participants now.

This study's planned enrollment of 174 is above the median of 18 across 16 interventional studies indexed under Acidosis, Respiratory.

Browse Acidosis, Respiratory studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Adult Patient admitted to the ED for acute exacerbation of (AE-COPD)and respiratory acidosis (PaCO2 > 45 mmHg and pH \<7.35), for whom ventilatory assistance by NIV is indicated (SPLF 2017, GOLD2023 recommendations)

Inclusion criteria

Inclusion Criteria:

  • Patients with ability to understand and give an
  • Patients affiliated with or who benefit from a social security
  • Patients admitted to the emergency department for a clinical suspicion of AE-COPD based on clinical history, physical examination and chest X-ray (SPLF 2017)
  • Patients with acute respiratory failure defined by: Respiratory rate ≥ 25 bpm AND/OR Signs of respiratory failure (use of accessory respiratory muscles, paradoxical abdominal movement)
  • Patients with respiratory acidosis defined by PaCO2 > 45 mmHg AND pH \< 7.35 (measured on arterial blood gas)

Exclusion criteria

Exclusion Criteria:

  • Patients who have already received NIV treatment before inclusion (including in-hospital or prehospital, with the exception of NIV at home)
  • to non-invasive ventilation (SPLF 2017 and GOLD 2023 recommendations)
  • Patient uncooperative, agitated, opponent of the technique
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Nasal high flow

    Nasal high flow will be administered through a heated humidifier (Airvo 3, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at 60 l/min, FiO2 will be adjusted to maintain an SpO2 88-92% and Initial temperature will be set at 37° and reduced according to patient's tolerance. Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment

    Device: Ventilatory support via nasal high flow

  • Active comparator
    Non invasive ventilation

    NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 88-92% and to patient's comfort. Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.

    Device: Ventilatory support via NIV

Interventions

  • DeviceVentilatory support via nasal high flow

    Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.

  • DeviceVentilatory support via NIV

    Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.

06

What researchers measure

Primary outcomes

  1. Change in PaCO2

    PaCO2 will be measured from standard laboratory arterial blood gas analysis before the initiation of ventilatory assistance and after 2 hours of treatment

    Time frame: 2 hours

Secondary outcomes

  1. Change in pH

    Blood gas parameters will be measured from standard laboratory arterial blood gas analysis before the initiation of ventilatory support and after 2 hours of treatment

    Time frame: 2 hours

  2. Change in PaO2

    Blood gas parameters will be measured from standard laboratory arterial blood gas analysis before the initiation of ventilatory support and after 2 hours of treatment

    Time frame: 2 hours

  3. Change in PaCO2

    Blood gas parameters will be measured from standard laboratory arterial blood gas analysis before the initiation of ventilatory support and after sessions of ventilatory support

    Time frame: up to 24 hours

  4. Change in pH

    Blood gas parameters will be measured from standard laboratory arterial blood gas analysis before the initiation of ventilatory support and after sessions of ventilatory support

    Time frame: up to 24 hours

  5. Change in PaO2

    Blood gas parameters will be measured from standard laboratory arterial blood gas analysis before the initiation of ventilatory support and after sessions of ventilatory support

    Time frame: up to 24 hours

  6. Respiratory rate

    Clinical parameters will be monitored by physician at baseline and throughout ventilatory support sessions, according to the international guidelines for NIV monitoring

    Time frame: up to 24 hours

  7. Signs of increased work of breathing (use of accessory respiratory muscles, paradoxical motion of the abdomen)

    Use of accessory respiratory muscles and paradoxical motion of the abdomen will be assessed by physician at baseline and after sessions of ventilatory support, on a 5 point likert scale (from 1 : absence to 5 : maximal use or accessory respiratory muscle and paradoxical motion of the abdomen)

    Time frame: up to 24 hours

  8. Perceived dyspnea

    Dyspnea will be assessed by the patient using a Modified Borg scale for dyspnea, at baseline and after sessions of ventilatory support. Difficulty of breathing will be quantified on a scale from 0 : no difficulty at all to 10 : breathing difficulty is maximal.

    Time frame: up to 24 hours

  9. Treatment failure (composite of change of treatment arm / need for invasive mechanical ventilation/ mortality)

    Failure will be defined by a composite of clinical or gasometric worsening or patient intolerance inducing a change of treatment arm/ need for orotracheal intubation and/or mortality (all causes).

    Time frame: Up to Day 28

  10. Weaning from ventilatory support

    Delay from initiation of ventilatory support to weaning

    Time frame: Up to Day 28

Other outcomes

  1. Hospitalization rate, including hospitalization in critical care units

    Proportion of patients requiring hospitalization following ED management

    Time frame: Day 28

  2. Readmission for AE-COPD

    Proportion of patients requiring emergency department admission for AE-COPD within 28 days from index admission

    Time frame: Day 28

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Nov 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2023
First posted
Nov 2, 2023
StartActual
Jun 16, 2026
Primary completionEst.
Nov 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06114667
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Jun 16, 2026
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Jun 22, 2026

Study contacts

Mustapha Sebbane, MD, PhD
Contact
m-sebbane@chu-montpellier.fr
+33 (4) 67 33 85 76
Sophie LEFEBVRE, PhD
Contact
s-lefebvre@chu-montpellier.fr
+33 (4) 67 33 85 76
Mustapha Sebbane, MD, PhD
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion